The Department of Surgery Resident Wellbeing Council
The Department of Surgery Resident Wellbeing Council exists to support all residents—junior and senior—in achieving optimal mental well-being during their training at Mass General and beyond.
About John Mullen, MD
Clinical Interests:
- Carcinoid tumor
- Desmoid tumor
- Gastrointestinal cancer
- Gastrointestinal stromal tumor (GIST)
- Melanoma
- Retroperitoneal sarcoma
- Soft tissue sarcoma
- Stomach (gastric) cancer
Treats:
- Adult
Locations
Mass General Surgery: Surgical Oncology
55 Fruit St.
7th Floor
Boston, MA 02114
Phone: 617-724-4000
Mass General Cancer Center in Waltham
52 Second Ave.
Suite 1110
Waltham, MA 02451
Phone: 781-487-6100
Medical Education
- MD, University of California, Davis
- Residency, Massachusetts General Hospital
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Fellowship, University of Texas - MD Anderson Cancer Center
American Board Certifications
- Surgery, American Board of Surgery
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
I am active in clinical and translational research in an effort to optimize the treatment and outcomes of patients with soft tissue sarcomas, desmoid tumors, and cancers of the stomach.
Current Translational Research Projects:
Principal Investigator. Comparative Genomics of Retroperitoneal Liposarcoma.
Current Prospective Clinical Trials:
Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas.
Phase I Trial of Bevacizumab, Metronomic Doxorubicin, and Radiation Therapy for Resectable Soft Tissue Sarcomas.
Publications
-
Select Publications:
- Ahmad R, Schmidt BH, Rattner DW, Mullen JT. Factors influencing readmission after curative gastrectomy for gastric cancer. J Am Coll Surg 2014;218:1215-1222.
- Schoenfeld JD, et al. The impact of positive margins on outcome among patients with gastric cancer treated with radiation. Am J Clin Oncol 2014;Feb 26 (epub ahead of print).
- Look-Hong NJ, Hornicek FJ, Harmon DC, et al. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year single institution retrospective study. Eur J Cancer 2012;49:875-883.
- Mullen JT et al. b-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist 2013;18:1043-1049.
- Mullen JT et al. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer 2014.